Abuse-deterrent opioid formulations: Are they a pipe dream?
- 1 February 2008
- journal article
- review article
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 10 (1) , 11-18
Abstract
The continued need for opioids to treat pain and their unavoidable link to abuse and addiction create a need for risk mitigation approaches that optimize their risk-benefit ratio. Abuse-deterrent formulations (ADFs) have emerged as a means for supporting opioid access while limiting abuse and its consequences. Several different types of ADFs have emerged including physical barriers to tampering, agonist-antagonist formulations, aversion, prodrugs, and alternative methods of administration. Each of these types has the potential to reduce specific forms of prescription opioid abuse. ADFs have the potential to reduce the public health burden of prescription opioid abuse, but they will require not only technically successful formulations, but also appropriate scientific assessment, widespread market penetration, and rational expectations of their benefits.Keywords
This publication has 25 references indexed in Scilit:
- Do Formulation Differences Alter Abuse Liability of Methylphenidate?Journal of Clinical Psychopharmacology, 2007
- Prescription opioid abuse among enrollees into methadone maintenance treatmentDrug and Alcohol Dependence, 2007
- PTI-821: sustained-release oxycodone using gel-cap technologyExpert Opinion on Investigational Drugs, 2007
- Making gains in painNature Reviews Drug Discovery, 2006
- Illicit Use of Specific Prescription Stimulants Among College Students: Prevalence, Motives, and Routes of AdministrationPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Ephemeral profiles of prescription drug and formulation tampering: Evolving pseudoscience on the InternetDrug and Alcohol Dependence, 2006
- Development of opioid formulations with limited diversion and abuse potentialDrug and Alcohol Dependence, 2006
- Development and Preliminary Experience with an Ease of Extractability Rating System for Prescription OpioidsDrug Development and Industrial Pharmacy, 2006
- A Profile of OxyContin AddictionJournal of Addictive Diseases, 2004
- Pentazocine - Naloxone: Another “Addiction-Proof Drug of Abuse”International Journal of the Addictions, 1987